Anti-Aging and Cell Therapy: Shift Bioscience Secures $16 Million in Funding
Funding Overview
Shift Bioscience is embarking on an ambitious journey to reverse aging through cellular reprogramming, leveraging cutting-edge gene discovery and artificial intelligence (AI). Recently, this Cambridge-based company secured $16 million in seed funding, directed by BGF, with Kindred Capital and Jonathan Milner also contributing.
Innovative Approach
This funding will significantly advance Shift's AI platform, which utilizes advanced simulations to predict gene-based interventions capable of rejuvenating human cells safely. By focusing on age-related diseases, the company aims to reprogram cells without inducing risky pluripotent states, ensuring a pioneering position in cellular reprogramming.
- CEO Insights: Daniel Ives highlights that the funding will catalyze research across several human cell types and animal models.
- Clinical Aspirations: This financial boost will also expedite clinical trials aimed at therapeutics for age-related conditions.
Understanding the Science
At the core of Shift Bioscience's initiatives is the epigenetic clock, a crucial biomarker reflecting biological age through DNA methylation changes. Developed by renowned scientist Steve Horvath, this clock provides a reliable means to gauge aging across human tissues.
In a quest to
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.